ACADIA Pharmaceuticals's Return On Capital Employed Insights
Portfolio Pulse from Benzinga Insights
ACADIA Pharmaceuticals reported Q1 sales of $118.46 million, but earnings decreased 3.11%, resulting in a loss of $43.02 million. The company posted a negative Return on Capital Employed (ROCE) of -0.11%, suggesting inefficient capital allocation.
May 23, 2023 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ACADIA Pharmaceuticals reported a Q1 loss of $43.02 million and a negative ROCE of -0.11%, indicating inefficient capital allocation.
ACADIA Pharmaceuticals reported a decrease in earnings and a negative ROCE, which suggests that the company is not effectively allocating its capital. This could negatively impact the stock price in the short term as investors may perceive the company as less efficient and less likely to achieve favorable long-term returns.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100